Trial · NCT02717455
Results by group56
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 56
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients Who Experienced Dose Limiting Toxicities (DLTs) | Stratum 1, Dose Level 1 (10 mg/m^2) | 0 | Participants | ||
| Number of Patients Who Experienced Dose Limiting Toxicities (DLTs) | Stratum 1, Dose Level 2 (16 mg/m^2) | 2 | Participants | ||
| Number of Patients Who Experienced Dose Limiting Toxicities (DLTs) | Stratum 2, Dose Level 1 (16 mg/m^2) | 0 | Participants | ||
| Number of Patients Who Experienced Dose Limiting Toxicities (DLTs) | Stratum 2, Dose Level 2 (22 mg/m^2) | 1 | Participants | ||
| Number of Patients Who Experienced Dose Limiting Toxicities (DLTs) | Stratum 2, Dose Level 3 (28 mg/m^2) | 4 | Participants | ||
| Number of Patients Who Experienced Dose Limiting Toxicities (DLTs) | Stratum 2, Dose Level 4 (36 mg/m^2) | 3 | Participants | ||
| Maximum Tolerated Dose (MTD) of Panobinostat in Stratum 1 | Stratum 1 | 10 | mg/m^2/day | ||
| Maximum Tolerated Dose (MTD) of Panobinostat in Stratum 2 | Stratum 2 | 22 | mg/m^2/day | ||
| Volume of Distribution (Vd) | Stratum 1, Dose Level 1 (10 mg/m^2) | 1704 | Standard Deviation 827 | L | |
| Volume of Distribution (Vd) | Stratum 1, Dose Level 2 (16 mg/m^2) | 2135 | Standard Deviation 1268 | L | |
| Volume of Distribution (Vd) | Stratum 2, Dose Level 1 (16 mg/m^2) | 3358 | Standard Deviation 1136 | L | |
| Volume of Distribution (Vd) | Stratum 2, Dose Level 2 (22 mg/m^2) | 2141 | Standard Deviation 906 | L | |
| Volume of Distribution (Vd) | Stratum 2, Dose Level 3 (28 mg/m^2) | 1967 | Standard Deviation 455 | L | |
| Volume of Distribution (Vd) | Stratum 2, Dose Level 4 (36 mg/m^2) | 2487 | Standard Deviation 2760 | L | |
| Elimination Rate (Kel) | Stratum 1, Dose Level 1 (10 mg/m^2) | 0.059 | Standard Deviation 0.024 | per hour | |
| Elimination Rate (Kel) | Stratum 1, Dose Level 2 (16 mg/m^2) | 0.065 | Standard Deviation 0.013 | per hour | |
| Elimination Rate (Kel) | Stratum 2, Dose Level 1 (16 mg/m^2) | 0.047 | Standard Deviation 0.003 | per hour | |
| Elimination Rate (Kel) | Stratum 2, Dose Level 2 (22 mg/m^2) | 0.057 | Standard Deviation 0.012 | per hour | |
| Elimination Rate (Kel) | Stratum 2, Dose Level 3 (28 mg/m^2) | 0.047 | Standard Deviation 0.006 | per hour | |
| Elimination Rate (Kel) | Stratum 2, Dose Level 4 (36 mg/m^2) | 0.066 | Standard Deviation 0.017 | per hour |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02717455/results